NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
|
|
- Clarence Garrett
- 6 years ago
- Views:
Transcription
1 TITLE VENOUS THROMBOEMBOLISM PROPHYLAXIS SCOPE Provincial Acute and Sub-Acute Care Facilities APPROVAL AUTHORITY Alberta Health Services Executive Committee SPONSOR Vice President, Quality and Chief Medical Officer Venous Thromboembolism Prophylaxis Policy (#PS-09) DOCUMENT # PS INITIAL EFFECTIVE DATE August 29, 2012 REVISION EFFECTIVE DATE SCHEDULED REVIEW DATE December 01, 2019 NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section. If you have any questions or comments regarding the information in this document, please contact the Policy & Forms Department at policy@ahs.ca. The Policy & Forms website is the official source of current approved policies, procedures, directives, standards, protocols and guidelines. OBJECTIVES To outline the recommended approach to venous thromboembolism (VTE) prophylaxis for all patients admitted to an Alberta Health Services acute and sub-acute care facility. Clinical judgment may be exercised when a situation is determined to be outside the parameters provided in this guideline. If a deviation from this guideline is determined to be appropriate or necessary, documentation of the rationale shall be included on the patient s health record. PRINCIPLES The underlying principle guiding the use of thromboprophylaxis in Alberta Health Services is that all acute and sub-acute care patients at risk receive thromboprophylaxis. An assessment of risk of venous thromboembolism and bleeding risk should be made by the most responsible health practitioner at the time of admission to an acute and/or sub-acute care facility. All health care professionals should identify patients who are at risk that are not receiving thromboprophylaxis or whose bleeding risk has subsided. This information is to be provided to the patient s health care team immediately. APPLICABILITY Compliance with this document is required by all Alberta Health Services employees, members of the medical and midwifery staffs, Students, Volunteers, and other persons acting on behalf of Alberta Health Services (including contracted service providers as necessary) working in Acute Care and Sub-Acute Facilities. Alberta Health Services (AHS) PAGE: 1 OF 17
2 ELEMENTS The approach to thromboprophylaxis in Alberta Health Services involves three steps: Step 1 Is Thromboprophylaxis NOT INDICATED? 1.1 For patients who are fully mobile and expected to have a length of stay less than 48 hours, thromboprophylaxis is generally not needed unless multiple other venous thromboembolism risk factors are present. 1.2 If no specific thromboprophylaxis is provided, patients should be encouraged to be as mobile as possible. 1.3 If a patient s clinical status changes significantly, a decision about thromboprophylaxis should be reassessed at that time. 1.4 For patients whose goals of care designation is Medical Care and Interventions, Focused on Comfort, anticoagulant prophylaxis is not given. See Alberta Health Services Advance Care Planning and Goals of Care Designation Policy and Procedure. Step 2 Is Anticoagulant Thromboprophylaxis CONTRAINDICATED? 1.1 Absolute contraindications to anticoagulant thromboprophylaxis are: a) active, clinically-important bleeding; b) platelets less than 30 x 10 9 /L; and/or c) major bleeding disorder. 1.2 Relative contraindications to anticoagulant thromboprophylaxis are: a) recent intracranial haemorrhage; b) recent paraspinal bleeding; and/or c) recent high-risk bleeding surgery. 1.3 For patients who are actively bleeding or have a high risk of bleeding, anticoagulant prophylaxis is not given. In this situation, intermittent pneumatic compression devices or bilateral, properly measured and fitted, calf-length graduated compression stockings are placed. a) These patients should be reassessed daily for proper use of the stockings/compression device and bleeding risk. When the high bleeding risk decreases, anticoagulants should be started. Alberta Health Services (AHS) PAGE: 2 OF 17
3 b) High Bleeding Risk Considerations in Hospitalized Patients: (i) peptic ulcer disease *; (ii) prior bleeding history *; (iii) thrombocytopenia *; (iv) (v) (vi) (vii) (viii) (ix) hepatic failure; rheumatic diseases; current cancer; age; renal failure; and/or Intensive Care Unit / Cardiac Care Unit stay. Note: * indicates high bleeding risk, either as a single factor or associated with other risk factors. 1.4 For patients with heparin-induced thrombocytopenia (HIT), either currently or in the past, unfractionated heparin (UFH) or low molecular weight heparin (LMWH) is contraindicated. In this setting, the internal medicine or haematology service should be contacted for advice the most appropriate anticoagulant thromboprophylaxis in the setting of heparin-induced thrombocytopenia is generally fondaparinux 2.5 milligrams (mg) subcutaneously (SC) once daily or intravenous argatroban. a) In order to avoid the higher risk of heparin-induced thrombocytopenia, use of unfractionated heparin should be minimized. 2.1 Assess risk of thromboembolism based on known risk factors: a) Major risk factors for thromboembolism: (i) (ii) (iii) (iv) (v) active cancer and its treatment; ischemic stroke or paralysis; trauma (especially of abdomen, pelvis and/or lower extremity); age greater than 75 years; major surgery (especially of abdomen, pelvis and/or lower extremity); Alberta Health Services (AHS) PAGE: 3 OF 17
4 (vi) congenital and/or acquired thrombophilia states; (vii) (viii) (ix) prior venous thromboembolism; intubated and mechanically ventilated; and/or spinal cord injury. b) Minor risk factors for Venous Thromboembolism: (i) (ii) (iii) (iv) (v) (vi) (vii) (viii) (ix) (x) (xi) (xii) (xiii) (xiv) (xv) age 60 to 74 years; general anesthesia greater than one (1) hour; obesity; sepsis; collagen vascular disease; inflammatory bowel disease; postpartum (six [6] weeks); severe respiratory disease; congestive heart failure; myeloproliferative disorders; pregnancy; varicose veins; estrogen therapy; nephrotic syndrome; and/or prolonged immobility greater than 24 hours. 2.2 See Table 1: Levels of Thromboembolism Risk and Recommended Thromboprophylaxis in Hospital Patients. Alberta Health Services (AHS) PAGE: 4 OF 17
5 Table 1 Levels of Thromboembolism Risk and Recommended Thromboprophylaxis in Hospital Patients. Level of venous thromboembolism risk (approximate deep vein thrombosis risk without prophylaxis) Low (Less than 10%) Risk Factors for venous thromboembolism Expected length of stay less than 72 hours Minor surgery Mobile medical Patient Suggested thromboprophylaxis options Early ambulation Moderate (10-40%) High (40-60%) Very High (40-80%) High bleeding risk Age less than 60 years Most general, gynaecology or urological surgery patients Immobilized medical patients Age greater than 75 years Major or multiple minor risk factors for venous thromboembolism Major abdominal surgery Major trauma Spinal cord injury Major cancer surgery Hip fracture Hip arthroplasty Knee arthroplasty low molecular weight heparin low dose unfractionated heparin bid or tid fondaparinux low molecular weight heparin low dose unfractionated heparin tid fondaparinux low molecular weight heparin Consider extended prophylaxis Vitamin K Antagonists Also Consider: fondaparinux Also Consider: rivaroxaban apixaban (Anti-Xa inhibitors) Mechanical prophylaxis with intermittent pneumatic compression Alberta Health Services (AHS) PAGE: 5 OF 17
6 DEFINITIONS TITLE EFFECTIVE DATE DOCUMENT # 2.3 For most patients, the recommended anticoagulant thromboprophylaxis is low molecular weight heparin once daily. a) In general, for weight less than 40 kilograms, it is recommended that a dose reduction be considered. b) In general, for weight greater than 100 kilograms (and body mass index [BMI] greater than 35), it is recommended that a dose increase be considered. For weight greater than 120 kilograms, even higher doses should be considered. c) A dosage reduction is recommended for prophylactic doses of low molecular weight heparins for patients with severe renal impairment (creatinine clearance [CrCl] less than millilitres/minute [ml/min]). For patients with creatinine clearance less than 20 ml/min, low dose unfractionated heparin prophylaxis is preferred over low molecular weight heparin. d) For arthroplasty patients, the first dose of low molecular weight heparin is generally given six (6) hours post-operatively and then daily. e) If patients are already receiving low molecular weight heparin and are scheduled for an epidural insertion, it is recommended that the anticoagulant be held for 18 to 24 hours prior to insertion. f) For patients with epidural catheters, the low molecular weight heparin dose is held to facilitate catheter removal in the morning and to allow for at least 18 hours after the previous low molecular weight heparin dose before catheter removal. For patients who have had an epidural catheter removed, the next dose of low molecular weight heparin should be delayed for at least two (2) hours after removal. Deep vein thrombosis means a thrombus ( blood clot ) occurring in one or more deep veins, especially in the legs, where it may produce leg swelling and/or pain. Goals of care designation means a codified instruction that provides direction regarding general care intentions, specific health interventions, transfer decisions and locations of care, for a patient as established after consultation between the most responsible health practitioner, patient and when appropriate, alternate decision-maker. Health care professional means an individual who is a member of a regulated health discipline, as defined by the Health Disciplines Act (Alberta) or the Health Professions Act (Alberta), and who practises within scope or role. Most responsible health practitioner means the health practitioner who has responsibility and accountability for the specific treatment/procedure(s) provided to a patient and who is Alberta Health Services (AHS) PAGE: 6 OF 17
7 authorized by Alberta Health Services to perform the duties required to fulfill the delivery of such a treatment/procedure(s) within the scope of his/her practice. Patient means an adult or child who receives or has requested health care or services from Alberta Health Services and its health care providers or individuals authorized to act on behalf of Alberta Health Services. This term is inclusive of residents, clients and outpatients. Thromboprophylaxis means the use of mechanical methods or anticoagulant medication to prevent venous thromboembolism from developing in patients who are at risk. Venous thromboembolism (VTE) means a thromboembolic event ( blood clot ) that develops within the venous system and includes both deep vein thrombosis and pulmonary embolism. REFERENCES Appendix A: Recommended Thromboprophylaxis Therapy by Patient Group Appendix B: Thromboprophylaxis Pharmacologic Dosing in Patients with Reduced Renal Function or Extremes of Weight Alberta Health Services Governance Documents o Advance Care Planning and Goals of Care Designation Policy and Procedure (#HCS - 38) o Venous Thromboembolism Prophylaxis Policy (#PS-09) VERSION HISTORY Date November 17, 2012 Action Taken Non-substantive change Revised Alberta Health Services (AHS) PAGE: 7 OF 17
8 APPENDIX A Recommended Thromboprophylaxis Therapy by Patient Group General Considerations: 1. Although the recommended options apply to most patients in each group, individual patient factors may suggest an alternate approach. 2. For all patients in whom it is possible and appropriate, early and frequent mobilization and ambulation are essential. 3. In general, for weight less than 40 kg or creatinine clearance less than 30 ml/min, it is suggested that the prophylactic low molecular weight heparin dose be reduced to the next lower pre-filled syringe dose for enoxaparin only. In general, for weight greater than 100 kg (and body mass index [BMI] greater than 35), consider doubling the low molecular weight heparin dose. At weights greater than 120 kg, even higher doses should be considered. 4. The duration of thromboprophylaxis is not based on pre-hospitalization mobility status alone. Given evidence suggesting low to moderate bleeding risk associated with use of prophylactic dosages of low molecular weight heparin, in absence of clinically significant bleeding or in setting of procedures involving critical areas where achieving hemostasis is limited or potentially catastrophic bleeding is possible, in most instances, thromboprophylaxis should not be withheld.[bump, 2008] Alberta Health Services (AHS) PAGE: 8 OF 17
9 Patient group Recommended Thromboprophylaxis Option High bleeding risk Intermittent pneumatic compression graduated compression stockings used continuously (except for bathing or ambulating) Neuraxial blockade / spinal anaesthesia Heparin-induced thrombocytopenia (HIT) unfractionated heparin bid/tid Can use low molecular weight heparin after epidural removed Suggest haematology / internal medicine consult No heparin or low molecular weight heparin fondaparinux 2.5 mg SC once daily (previous heparin-induced thrombocytopenia) argatroban IV (current heparin-induced thrombocytopenia) Initiation ASAP after emergency admission Just prior to surgery for elective surgical procedures unfractionated heparin hold hours prior to procedure and hold four (4) hours post procedure low molecular weight heparin hold hours prior to procedure and hold four (4) hours post procedure As soon as the diagnosis of heparin-induced thrombocytopenia considered Duration Until bleeding risk allows the use of anticoagulants Discharge and platelet count greater than 120 x 10 9 /L Alberta Health Services (AHS) PAGE: 9 OF 17
10 Patient group Recommended Thromboprophylaxis Option Burn unit patients low molecular weight heparin every 24 hours or low dose unfractionated heparin bid/tid Cardiovascular surgery Chronic kidney disease Critical care low molecular weight heparin every 24 hours or low dose unfractionated heparin bid/tid Initiation When there is evidence of primary hemostasis Primary hemostasis Duration unfractionated heparin bid/tid On admission Use Critical Care order sets In most cases, the prophylaxis is low molecular weight heparin every 24 hours or low dose unfractionated heparin bid/tid graduated compression stockings until anticoagulants can be started First dosing time after admission, if possible See Critical Care order sets Include thromboprophylaxis in transfer orders Alberta Health Services (AHS) PAGE: 10 OF 17
11 General surgery (major) Use General Surgery order sets In most cases, the prophylaxis is low molecular weight heparin every 24 hours or low dose unfractionated heparin bid/tid graduated compression stockings until low molecular weight heparin can be started Zero one (0-1) hour pre-op (if no epidural) or Four (4) hours after insertion of epidural Post-op day one if bleeding concerns Consider extended prophylaxis for abdominopelvic cancer surgeries Gynaecology Use Gynaecology order sets In most cases, the prophylaxis is low molecular weight heparin every 24 hours or low dose unfractionated heparin bid/tid graduated compression stockings or until anticoagulants can be started First dosing time after emergency room admission or post-op or The following morning if there are bleeding concerns Consider extended prophylaxis for abdominopelvic cancer surgeries Alberta Health Services (AHS) PAGE: 11 OF 17
12 Hip & knee arthroplasty Use Arthroplasty order sets In most cases, the prophylaxis is low molecular weight heparin every 24 hours For patients with moderate renal dysfunction, use dose reduced low molecular weight heparin SC every 24 hours or low dose unfractionated heparin bid Six-eight (6 8) hours post-op 15 days 28 days if higher risk and total hip replacement Or fondaparinux or rivaroxaban/apixaban or vitamin K antagonist Hip fracture Use Hip Fracture admission and postop order sets low molecular weight heparin every 24 hours or fondaparinux or warfarin If surgery is delayed, start low molecular weight heparin on admission days Dosage reduction if weight less than 40 kg or creatinine clearance less than 30 ml/min Alberta Health Services (AHS) PAGE: 12 OF 17
13 Internal medicine (and medical subspecialties) Use Medicine admission order sets / deep vein thrombosis prophylaxis order sets For most Patients, low molecular weight heparin every 24 hours First dosing time after admission Consider extended for cancer, stroke or low dose unfractionated heparin bid/tid or fondaparinux Dosage adjustment for high or low weight and renal dysfunction graduated compression stockings until anticoagulant can be started Neurosurgery graduated compression stockings until anticoagulant can be started low molecular weight heparin every 24 hours or low dose unfractionated heparin bid/tid or start with intermittent pneumatic compression / bilateral calf-length graduated compression stockings and switch to low molecular weight heparin when risk of bleeding decreases For intermittent pneumatic compression/graduated compression stockings, start just prior to surgery for elective surgical procedure and ASAP after admission for major neurotrauma or non-traumatic intracranial haemorrhage For low molecular weight heparin, no sooner than day after surgery Alberta Health Services (AHS) PAGE: 13 OF 17
14 Obstetrics low molecular weight heparin every 24 hours Oncology (medical and radiation) Paediatrics low molecular weight heparin every 24 hours graduated compression stockings until low molecular weight heparin can be started Early mobilization except in very high risk population No clear evidence supporting thromboprophylaxis in paediatric population Plastic surgery low molecular weight heparin, every 24 hours, fondaparinux, low dose unfractionated heparin bid/tid Initial dose of unfractionated heparin given immediately post caesarean for high risk individuals low molecular weight heparin started at least two (2) hours after epidural removed First dosing time after admission Pre-op or post-op six-twelve (6-12) hours Extended for six (6) weeks and/or converted to warfarin for those with prior venous thromboembolism or with thrombophilia Consider benefits vs. risk of post-discharge or extended thromboprophylaxis Alberta Health Services (AHS) PAGE: 14 OF 17
15 Spinal cord injury low molecular weight heparin every 12 or 24 hours Spine surgery low molecular weight heparin every 24 hours Stroke ischemic Stroke haemorrhagic Use Stroke admission order sets For most patients, low molecular weight heparin every 24 hours Dosage adjustment for low or high weight and renal dysfunction graduated compression stockings until low molecular weight heparin can be started Use Stroke admission order sets Intermittent pneumatic compression or bilateral, properly-fitted, calf-length graduated compression stockings After approximately five seven (5 7) days, consider switch to low molecular weight heparin as for ischemic stroke ASAP after admission (once hemostasis is evident) Evening or morning after surgery First dosing time after admission On admission from rehab, consider extended prophylaxis six-twelve (6-12) weeks Consider extended prophylaxis for hemiplegia for sixtwelve (6-12) weeks Alberta Health Services (AHS) PAGE: 15 OF 17
16 Sub-acute care low molecular weight heparin every 24 hours or low dose unfractionated heparin bid Trauma Urology For extended prophylaxis in spinal cord injury, stroke associated with paralysis, hip fracture or total joint and abdominal/pelvic cancer therapy graduated compression stockings until low molecular weight heparin can be started Usual risk patients: low molecular weight heparin every 24 hours High risk patients (lower extremity fracture): low molecular weight heparin every 12 hours Use Urology order sets In most cases, the prophylaxis is low molecular weight heparin every 24 hours or low dose unfractionated heparin bid graduated compression stockings until low molecular weight heparin can be started Continuation of prophylaxis at transitions ASAP after admission (once hemostasis is evident) Options: First dosing time after surgery Morning after surgery if there are bleeding concerns First dosing time after emergency room admission or post-op days from rehabilitation Alberta Health Services (AHS) PAGE: 16 OF 17
17 Drug Thromboprophylaxis Pharmacologic Dosing in Patients with Reduced Renal Function or Extremes of Weight Reduced renal function Creatinine Clearance less than 30 ml/min Obesity Weight greater than 100 kg (and BMI greater than 35) Low weight Weight less than 40 kg enoxaparin mg subcutaneously daily mg subcutaneously twice daily mg subcutaneously daily APPENDIX B dalteparin units subcutaneously daily 7500 units subcutaneously daily 2500 units subcutaneously daily tinzaparin No adjustment 75 units/kg subcutaneously daily 75 units/kg subcutaneously daily unfractionated heparin 5000 units subcutaneously twice daily 5000 units subcutaneously every eight (8) hours 5000 units subcutaneously twice daily Note: Monitoring anti-xa levels may be useful in selected patients. Note: At weights greater than 120 kg, even higher doses should be considered. Alberta Health Services (AHS) PAGE: 17 OF 17
Venous Thromboembolism Prophylaxis
Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January
More informationTHROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY
THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY OBJECTIVE: To outline a practical approach for the prevention of venous thromboembolism (VTE) in patients undergoing non-orthopedic surgery. BACKGROUND: VTE is
More informationINDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY
INDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY N.E. Pearce INTRODUCTION Preventable death Cause of morbidity and mortality Risk factors Pulmonary embolism
More informationVenous Thromboembolism. Prevention
Venous Thromboembolism Prevention August 2010 Venous Thromboembloism Prevention 1 1 Expected Practice Assess all patients upon admission to the ICU for risk factors of venous thromboembolism (VTE) and
More information1. SCOPE of GUIDELINE:
Page 1 of 35 CLINICAL PRACTICE GUIDELINE: Venous Thromboembolism (VTE) Prevention Guideline: Thromboprophylaxis AUTHORIZATION: VP, Medicine Date Approved: May 17, 2012 Date Revised: Vancouver Coastal Health
More informationObjectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?
Objectives Venous Thromboembolism (VTE) Prophylaxis Rishi Garg, MD Department of Medicine Identify patients at risk for VTE Options for VTE prophylaxis Current Recommendations (based on The Seventh ACCP
More informationPerioperative VTE Prophylaxis
Perioperative VTE Prophylaxis Gregory J. Misky, M.D. Assistant Professor of Medicine University Of Colorado Denver You recommend the following 72 y.o. man admitted for an elective R hip repair. Patient
More informationMisunderstandings of Venous thromboembolism prophylaxis
Misunderstandings of Venous thromboembolism prophylaxis Veerendra Chadachan Senior Consultant Dept of General Medicine (Vascular Medicine and Hypertension) Tan Tock Seng Hospital, Singapore Case scenario
More informationVenous Thromboembolism Prophylaxis: Checked!
Venous Thromboembolism Prophylaxis: Checked! William Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University of Toronto National Lead, VTE Prevention, Safer
More informationVenous thromboembolism - reducing the risk
Venous thromboembolism - reducing the risk Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital NICE guideline Draft for consultation,
More informationAnticoagulation for prevention of venous thromboembolism
Anticoagulation for prevention of venous thromboembolism Original article by: Michael Tam Note: updated in June 2009 with the eighth edition (from the seventh) evidence-based clinical practice guidelines
More informationTHROMBOSIS RISK FACTOR ASSESSMENT
Name: Procedure: Doctor: Date: THROMBOSIS RISK FACTOR ASSESSMENT CHOOSE ALL THAT APPLY EACH RISK FACTOR REPRESENTS 1 POINT Age 41 60 years Minor Surgery Planned History of Prior Major Surgery (< 1 month)
More informationGuideline Quick View: Venous Thromboembolism
Guideline Quick View: Venous Thromboembolism The AORN Guideline Quick View is a key component of Guideline Essentials, a suite of online implementation tools designed to help the perioperative team translate
More informationThese are guidelines only and can be deviated from if it is thought to be in the patient s best interest.
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics Venous thromboembolism (VTE) is a recognised complication associated with inactivity and surgical procedures. Therefore, all
More informationVenous thromboembolism: reducing the risk
Issue date: January 2010 Venous thromboembolism: reducing the risk Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital This guideline
More informationPrevention of Venous Thromboembolism
Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH President and CEO Dale W. Bratzler, DO, MPH Oklahoma Foundation for Medical Quality QIOSC Medical Director
More informationGetting Started Kit VENOUS THROMBOEMBOLISM PREVENTION. Section 2: Evidence-Based Appropriate VTE Prophylaxis
Reducing Harm Improving Healthcare Protecting Canadians VENOUS THROMBOEMBOLISM PREVENTION Getting Started Kit Section 2: Evidence-Based Appropriate VTE Prophylaxis January 2017 www.patientsafetyinstitute.ca
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE INFLUENZA IMMUNIZATION SCOPE Provincial APPROVAL AUTHORITY Vice-President and Chief Health Operations Officer, Central and Southern Alberta SPONSOR Population, Public and Indigenous Health PARENT
More informationSlide 1. Slide 2. Slide 3. Outline of This Presentation
Slide 1 Current Approaches to Venous Thromboembolism Prevention in Orthopedic Patients Hujefa Vora, MD Maria Fox, RN June 9, 2017 Slide 2 Slide 3 Outline of This Presentation Pathophysiology of venous
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationDVT - initial management NSCCG
Background information Information resources for patients and carers Updates to this care map Synonyms Below knee DVT and bleeding risks Patient with confirmed DVT Scan confirms superficial thrombophlebitis
More informationVenothromboembolism prophylaxis: Trauma and Orthopaedics Clinical guideline, V2
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics 11/11/11 TEMPORARY GUIDANCE There is no prophylactic tinzaparin available in the Trust currently. Please substitute enoxaparin
More informationVenous Thromboembolism (VTE) Prevention
Venous Thromboembolism (VTE) Prevention 7 VTE Risk Assessment: General Patient Population Assess VTE risk at admission, post-op, and transfer See page 2 for VTE risk assessment among Obstetrical (OB) patients
More informationNICE Guidance: Venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital 1
The College of Emergency Medicine Patron: HRH The Princess Royal Churchill House Tel +44 (0)207 404 1999 35 Red Lion Square Fax +44 (0)207 067 1267 London WC1R 4SG www.collemergencymed.ac.uk CLINICAL EFFECTIVENESS
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE PNEUMOCOCCAL IMMUNIZATION SCOPE Provincial APPROVAL AUTHORITY Vice-President and Chief Health Operations Officer, Central and Southern Alberta SPONSOR Population, Public and Indigenous Health PARENT
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationProphylaxis for Hospitalized and Non-Hospitalized Medical Patients
Prophylaxis for Hospitalized and Non-Hospitalized Medical Patients An Educational Slide Set American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism Slide set authors: Eric
More informationDENOMINATOR: All surgical patients aged 18 years and older undergoing procedures for which VTE prophylaxis is indicated in all patients
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2017 OPTIONS FOR INDIVIDUAL MEASURES:
More informationTarkten A Pharr, MD, FACS 04/26/2018. VTE Prevention Strategies: Is a One Size Fits all Approach Correct?
Tarkten A Pharr, MD, FACS 04/26/2018 VTE Prevention Strategies: Is a One Size Fits all Approach No disclosures... Why do we care? Where is this is the realm of public health concerns? Incidence/Prevalence
More informationPrevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales
Prevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales Merimbula, 6 th November 2010 University of Sydney Department of Surgery Westmead Hospital
More information*Corresponding Author:
Audit of venous thromboembolism prophylaxis administered to general surgical patients undergoing elective and emergency operations at National Hospital, Sri Lanka *Migara Seneviratne 1, Asanka Hemachandra
More informationEarly Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Marilyn Szekendi, PhD, RN
Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement Marilyn Szekendi, PhD, RN ANA 7 th Annual Nursing Quality Conference, February 2013 Research Team Banafsheh Sadeghi,
More informationGeneral. Recommendations. Guideline Title. Bibliographic Source(s) Guideline Status. Major Recommendations
General Guideline Title Prevention of deep vein thrombosis and pulmonary embolism. Bibliographic Source(s) American College of Obstetricians and Gynecologists (ACOG). Prevention of deep vein thrombosis
More informationVTE Management in Surgical Patients: Optimizing Prophylaxis Strategies
VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies VTE in Surgical Patients: Recognizing the Patients at Risk Pathogenesis of thrombosis: Virchow s triad and VTE Risk Hypercoagulability
More information10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline
Disclosures Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines No relevant conflicts of interest related to the topic presented. Cyndy Brocklebank, PharmD, CDE Chronic Disease Management
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationReducing the risk of venous thrombo-embolism (VTE) in hospital and after discharge
Reducing the risk of venous thrombo-embolism (VTE) in hospital and after discharge What is a venous thromboembolism (VTE)? This is a medical term that describes a blood clot that develops in a deep vein
More informationVenous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community
Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationCPT only copyright 2014 American Medical Association. All rights reserved. 12/23/2014 Page 66 of 593
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2015 PQRS OPTIONS FOR INDIVIDUAL MEASURES:
More informationNoCVA Hospital Engagement Network SSI/VTE Safe Surgery Collaborative. December 13, 2012
NoCVA Hospital Engagement Network SSI/VTE Safe Surgery Collaborative December 13, 2012 1 Hospital Acquired VTE Preventing a Preventable Problem It takes a commitment from ALL members of the healthcare
More informationTRANSPARENCY COMMITTEE OPINION. 18 April 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 April 2007 ARIXTRA 2.5 mg/0.5 ml, solution for injection in prefilled syringe Pack of 2 (CIP: 359 225-4) Pack of
More informationVTE Prevention Guidelines (Venous Thromboembolism) (Venous Thromboembolism)
VTE Prevention Guidelines (Venous Thromboembolism) (Venous Thromboembolism) When using this document please ensure that the version you are using is the most up to date either by checking on the Trust
More informationCancer and Thrombosis
Cancer and Thrombosis The close relationship between venous thromboembolism and cancer has been known since at least the 19th century by Armand Trousseau. Thrombosis is a major cause of morbidity and mortality
More informationIF YOU RECEIVED THIS FACSIMILE IN ERROR, PLEASE CALL IMMEDIATELY. ADMISSION INSTRUCTIONS: Admitted to Dr.
ADMISSION INSTRUCTIONS: Admitted to Dr. Procedure: Right Hip Left Hip CODE STATUS: Full DNR level of intervention DIET: Dysphagia screen consult SLP High protein, high energy Regular Nutrient dense Boost
More informationVenous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital
Venous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital VTE is common and dangerous 5 VTE is Common VTE Incidence: 1.5 / 1000 per year
More informationADULT TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) TELEMETRY BED TRANSFER ORDERS 1 of 4
TELEMETRY BED TRANSFER 1 of 4 9 Actual 9 Estimated Patient ID Area Weight kg 9 Actual 9 Estimated Height cm ALLERGIES: REFER TO ALLERGY PROFILE/ POWERCHART Transfer to: 10 South Attending Physician: Diagnosis:
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationVenous Thromboembolism (VTE) Prevention and Treatment of VTE in Patients Admitted to Hospital
Please Note: This policy is currently under review and is still fit for purpose. Venous Thromboembolism (VTE) Prevention and Treatment of VTE in Patients Admitted to Hospital This procedural document supersedes
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationVENOUS THROMBOEMBOLISM (VTE) PREVENTION MEDICAL PROVIDER EDUCATION JUNE 2017
VENOUS THROMBOEMBOLISM (VTE) PREVENTION MEDICAL PROVIDER EDUCATION JUNE 2017 VTE IS THE 2 ND MOST COMMON HOSPITAL ACQUIRED CONDITION RISK FACTORS DECREASED ACTIVITY = VTE RISK (NURSES MEASURE WITH BRADEN
More informationOrthopedic Admission Hip Fracture Version 2 1/25/2017
Patient Name: Initial each page and Sign/Date/Time last page Diagnosis: Allergies with reaction type: Orthopedic Admission Hip Fracture Version 2 1/25/2017 Patient Placement Patient Status If the physician
More informationGENERAL SURGICAL ADULT POST-OPERATIVE ORDERS 1 of 4
down ADULT POST-OPERATIVE 1 of 4 9 Actual 9 Estimated Patient ID Area Weight kg 9 Actual 9 Estimated Height cm ALLERGIES: REFER TO ALLERGY PROFILE/ POWERCHART Admit to: Post Anesthesia Care Unit (PACU),
More informationWhat You Should Know
1 New 2018 ASH Clinical Practice Guidelines on Venous Thromboembolism: What You Should Know New 2018 ASH Clinical Practice Guidelines on Venous Thromboembolism: What You Should Know The American Society
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationAre guidelines for anticoagulation useful in cancer patients?
Session 3 Striking a Balance Between Bleeding and the Risk of Thrombosis in Cancer Patients Are guidelines for anticoagulation useful in cancer patients? Sebastian Szmit Department of Pulmonary Circulation
More informationNew v1.0 Date: December 2015 Patricia Wain - Associate Director Physical Care. Kenny Laing - Deputy Director of Nursing
Clinical Venous Thromboembolism: Standing Operating Procedure Document Control Summary Status: Version: Author/Title: Owner/Title: New v1.0 Date: December 2015 Patricia Wain - Associate Director Physical
More informationNICE guideline Published: 21 March 2018 nice.org.uk/guidance/ng89
Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism NICE guideline Published: 21 March 2018 nice.org.uk/guidance/ng89 NICE 2018. All rights
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More information4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients
4.7 Algorithm for the Peri-operative Management of Anticoagulants and Antiplatelet agents in Adult patients Assess Thrombosis risk: baseline risk in an individual patient plus additional thrombotic risk
More informationDeep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H
Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H Authors' objectives To systematically review the incidence of deep vein
More informationDeep Vein Thrombosis
Deep Vein Thrombosis from NHS (UK) guidelines Introduction Deep vein thrombosis (DVT) is a blood clot in one of the deep veins in the body. Blood clots that develop in a vein are also known as venous thrombosis.
More informationThromboprophylaxis in Adult General Medical Patients - Guidelines for Management
Thromboprophylaxis in Adult General Medical Patients - Guidelines for Management Adapted from the Worcestershire Acute Hospitals NHS Trust Guideline WAHT-MED-010 Version: Final Ratified by: Provider Quality
More informationAdmit date (YYYY/MM/DD): Cardiologist On-Call: Diagnosis: Lab Tests. CBC, Electrolytes, Urea, Creatinine, Glucose, INR, PTT, Urinalysis
of nurse 1. Admit under ward Attending Physician: Dr. Admit date (YYYY/MM/DD): Cardiologist On-Call: Diagnosis: Lab Tests 2. On admission (if not already performed in Emergency Department or in Coronary
More informationLow Risk Non-surgical medicine patients without any Mechanical prophylaxis
ADULT VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS GUIDELINE This document is intended as a guideline only and should not replace sound clinical judgment. I. VTE risk assessment and selection of prophylaxis:
More informationShared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Version 5.2 Version: 5.2 Authorised by: Joint Medicines
More informationWMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT
WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT - Entering orders for anticoagulation in Cerner Providers will enter individual orders (oneoffs)
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationGuidelines for Prevention of Venous Thromboembolism in Adults
Guidelines for Prevention of Venous Thromboembolism in Adults First Edition (2011) www.savte.com Dear Colleagues, It is our pleasure to introduce this booklet of guidelines for venous thromboembolism (VTE)
More informationADULT CARDIAC SURGERY TELEMETRY BED TRANSFER ORDERS 1 of 4
ADULT CARDIAC SURGERY TELEMETRY BED TRANSFER 1 of 4 9 Actual 9 Estimated Attending Surgeon: Medical Record Number Weight kg 9 Actual 9 Estimated Height cm ALLERGIES: REFER TO ALLERGY PROFILE/ POWERCHART
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationCANCER ASSOCIATED THROMBOSIS. Pankaj Handa Department of General Medicine Tan Tock Seng Hospital
CANCER ASSOCIATED THROMBOSIS Pankaj Handa Department of General Medicine Tan Tock Seng Hospital My Talk Today 1.Introduction 2. Are All Cancer Patients at Risk of VTE? 3. Should All VTE Patients Be Screened
More informationGUIDELINE FOR THROMBOPROPHYLAXIS IN ADULT (18 YEARS AND OLDER) IN GENERAL MEDICAL PATIENTS AND INPATIENTS UNDERGOING SURGERY
GUIDELINE FOR THROMBOPROPHYLAXIS IN ADULT (18 YEARS AND OLDER) IN GENERAL MEDICAL PATIENTS AND INPATIENTS UNDERGOING SURGERY SEE SEPARATE GUIDELINES FOR THROMBOPROPHYLAXIS IN OBSTETRICS This guidance does
More informationVenous Thromboembolism Prophylaxis
I CSI Health Care Guideline: Venous Thromboembolism Prophylaxis I NSTITUTE FOR CLINICAL S YSTEMS IMPROVEMENT Eighth Edition September 2011 The information contained in this ICSI Health Care Guideline is
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE SAFE BATHING TEMPERATURES AND FREQUENCY SCOPE Provincial: Continuing Care APPROVAL AUTHORITY Vice President SPONSOR Seniors Health PARENT DOCUMENT TITLE, TYPE AND NUMBER Policy: Safe Bathing Temperatures
More informationFactor Xa Inhibition in the Management of Venous Thromboembolism: Important Safety Information. Important Safety Information (cont d)
Factor Xa Inhibition in the Management of Venous Thromboembolism: The Role of Fondaparinux WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with
More informationConsensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture
Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture Patients with hip fractures should be operated on within 36 hours of presentation wherever possible.
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationGUIDELINES FOR THE PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) IN MEDICAL AND SURGICAL INPATIENTS ON THE MDGH SITE
GUIDELINES FOR THE PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) IN MEDICAL AND SURGICAL INPATIENTS ON THE MDGH SITE This local guideline has been produced as an aid to risk assessment and prevention
More informationThromboprophylaxis Guidelines for Adult Patients in: Medicine, Haematology & Oncology, Intensive Care Unit, Surgery, Orthopaedics, Major Trauma.
2015 Thromboprophylaxis Guidelines for Adult Patients in: Medicine, Haematology & Oncology, Intensive Care Unit, Surgery, Orthopaedics, Major Trauma. Title Thromboprophylaxis guidelines for adult patients
More informationMeasure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) 2013 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage
More informationEAU GUIDELINES ON THROMBOPROPHYLAXIS IN UROLOGICAL SURGERY
EAU GUIDELINES ON THROMBOPROPHYLAXIS IN UROLOGICAL SURGERY K.A.O. Tikkinen (Chair), R. Cartwright, M.K. Gould, R. Naspro, G. Novara, P.M. Sandset, P.D. Violette, G.H. Guyatt Introduction Utilising recent
More informationAppendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS
Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS Please note that newer oral anticoagulants e.g. rivaroxaban, dabigatran and apixiban should be only be considered in patients with
More informationOBSTETRIC ADMISSION ORDERS 1 of 4
OBSTETRIC ADMISSION 1 of 4 Actual Estimated Weight kg Actual Estimated Height cm ALLERGIES: REFER TO ALLERGY PROFILE/ POWERCHART ADMIT TO: Labor and Delivery ( ) Check, circle and/or fill in all orders
More informationHEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,
More informationTHROMBOPROPHYLAXIS POLICY FOR ADULT PATIENTS ADMITTED AS INPATIENTS. 362 Version No: 2 Previous Trust / LHB Ref No:
Reference No: THROMBOPROPHYLAXIS POLICY FOR ADULT PATIENTS ADMITTED AS INPATIENTS 362 Version No: 2 Previous Trust / LHB Ref No: 362 Documents to read alongside this Policy, Procedure etc (delete as necessary)
More informationInhixa (Enoxaparin Sodium)
Inhixa (Enoxaparin Sodium) P R E V ENTIS SAFETY D E V I C E P R E V E N T I S I S A N AU TO M AT I C N E E D L E S H I E L D I N G S Y S T E M, W H I C H H A S A C O V E R T H AT E X T E N D S O V E R
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE SCOPE Provincial APPROVAL AUTHORITY Clinical Operations Executive Committee SPONSOR Pharmacy Services PARENT DOCUMENT TITLE, TYPE AND NUMBER Not applicable DOCUMENT # INITIAL EFFECTIVE DATE REVISION
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE GLYCEMIC MANAGEMENT - ADULT SCOPE Provincial: Acute Care APPROVAL AUTHORITY Clinical Operations Executive Committee SPONSOR Diabetes, Obesity & Nutrition Strategic Clinical Network PARENT DOCUMENT
More informationDr. Steve Ligertwood Dr. Roderick Tukker Dr. David Wilton
Dr. Steve Ligertwood Hospitalist Royal Columbian Hospital Regional Department Head-Hospitalist for Fraser Health Authority Project Lead BC Hospitalist VTE Collaborative Clinical Instructor, UBC School
More informationPrevention of Venous Thromboembolism
Prevention of Venous Thromboembolism Reference No: P_CS_05 Version 2.4 Ratified by: LCHS Trust Board Date ratified: 27 th January 2015 Name of originator / author: Medical Director Name of responsible
More informationThe Royal College of Emergency Medicine. VTE Risk in Lower Limb Immobilisation in Plaster Cast 2015/2016
The Royal College of Emergency Medicine Clinical Audits VTE Risk in Lower Limb Immobilisation in Plaster Cast Introduction 2015/2016 EXCELLENCE IN EMERGENCY MEDICINE A significant number of patients attend
More informationP-RMS: LT/H/PSUR/0004/001
Core Safety Profile Active substance: Dalteparine Pharmaceutical form(s)/strength: Solution for injection, 2500 I.U./0.2ml, 2500 I.U./ml, 5000 I.U./0.2ml, 7500 I.U./0.3ml, 7500 I.U./0.75ml, 10000 I.U./0.4ml,
More informationCoversheet for Network Site Specific Group Agreed Documentation
Coversheet for Network Site Specific Group Agreed Documentation This sheet is to accompany all documentation agreed by Pan Birmingham Cancer Network Site Specific Groups. This will assist the Network Governance
More informationPreventing Blood Clots in Adult Patients
Manchester Royal Eye Hospital Surgical Services Information for Patients Preventing Blood Clots in Adult Patients This leaflet will give you information on how to reduce the risk of developing blood clots
More information